Failing the public health--rofecoxib, Merck, and the FDA.
Topol
Eric J
EJ
Cleveland Clinic Foundation, Cleveland, USA.
D016907:Adverse Drug Reaction Reporting Systems; D000329:Advertising; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000266:history; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000266:history; D017277:Drug Approval / Q000266:history; D004345:Drug Industry / Q000266:history / Q000331:legislation & jurisprudence; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000266:history; D009203:Myocardial Infarction / Q000139:chemically induced*; D012306:Risk; D020521:Stroke / Q000139:chemically induced; D013450:Sulfones; D014481:United States; D014486:United States Food and Drug Administration / Q000266:history
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib